Eisai’s Banzel OKed as epilepsy treatment
WOODCLIFF LAKE, N.J. — The Food and Drug Administration has approved a drug made by Eisai to treat a rare form of epilepsy, the drug maker said Friday.
The FDA approved Banzel (rufinamide) oral suspension for the treatment of seizures in children and adults with Lennox-Gastaut syndrome. The condition, also called LGS, affects 1% to 4% of children with epilepsy.
“This new formulation provides an option for patients who may prefer a liquid or find it difficult to take the medication in tablet form,” Eisai president and CEO Lonnel Coats said.
Hospira launches catalog of U.S. products on website
LAKE FOREST, Ill. — Hospira launched a new online resource that catalogs all of its products available in the United States.
Hospira said that the U.S. product catalog, available at Hospira.com/catalog, allows customers, including healthcare facilities and medical care providers, to search Hospira’s more than 1,200 products in a variety of ways: alphabetically, by product name, by list number or by therapeutic class.
"In designing the website, we focused on providing customers with access to a broad array of product information, while at the same time ensuring [that] the ability to search for information is both simple and intuitive," said Thomas Moore, president, U.S. for Hospira. "Our vision is to provide customers a comprehensive resource where they can research, experience and order products."
Click here to visit the site.
Endo elects new board member
CHADDS FORD, Pa. — Endo’s board of directors has expanded to nine members with the addition of David Nash.
Nash, who is the founding dean of the Jefferson School of Population Health at Thomas Jefferson University in Philadelphia, also serves as a board member for Humana.
Endo chairman, Roger Kimmel, said the board welcomes Nash’s contributions as Endo continues to diversify its business.